Evidence map›Paper›PMID 32135429›Full record

Trial reportDrug and alcohol dependence2020

Parallel modeling of pain and depression in prediction of relapse during buprenorphine and naloxone treatment: A finite mixture model.

Noel A Vest, Sterling McPherson, G Leonard Burns, Sarah Tragesser

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Noel A VestWashington State University, Department of Psychology, Pullman, WA 99164-4820, United States. Electronic address: noelvest@stanford.edu.
Sterling McPhersonWashington State University, Elson S. Floyd College of Medicine, Analytics & Psychopharmacology Laboratory (APPL), 412 E. Spokane Falls Blvd. Spokane, WA 99202-2131, United States. Electronic address: sterling.mcpherson@wsu.edu.
G Leonard BurnsWashington State University, Department of Psychology, Pullman, WA 99164-4820, United States. Electronic address: glburns@wsu.edu.
Sarah TragesserWashington State University, Department of Psychology, Pullman, WA 99164-4820, United States. Electronic address: sarah_tragesser@wsu.edu.
Washington State University · USWashington State University Spokane · US

Funding

Interdisciplinary Research Training in Pain and Substance Use DisordersT32DA035165 · NIDA · STANFORD UNIVERSITY · PI SEAN C MACKEY · 2013 to 2026
$7.2M
NIDA NIH HHS T32 DA035165
6 · The paper itself

Abstract

backgroundRelapse is common in treatment for opioid use disorders (OUDs). Pain and depression often co-occur during OUD treatment, yet little is known about how they influence relapse among patients with a primary diagnosis of prescription opioid use disorder (POUD). Advanced statistical analyses that can simultaneously model these two conditions may lead to targeted clinical interventions.

methodThe objective of this study was to utilize a discrete survival analysis with a growth mixture model to test time to prescription opioid relapse, predicted by parallel growth trajectories of depression and pain, in a clinical sample of patients in buprenorphine/naloxone treatment. The latent class analysis characterized heterogeneity with data collected from the National Institute of Drug Abuse Clinical Trials Network project (CTN-0030).

resultsResults suggested that a 4-class solution was the most parsimonious based on global fit indices and clinical relevance. The 4 classes identified were: 1) low relapse, 2) high depression and moderate pain, 3) high pain, and 4) high relapse. Odds ratios for time-to-first use indicated no statistically significant difference in time to relapse between the high pain and the high depression classes, but all other classes differed significantly.

conclusionThis is the first longitudinal study to characterize the influence of pain, depression, and relapse in patients receiving buprenorphine and naloxone treatment. These results emphasize the need to monitor the influence of pain and depression during stabilization on buprenorphine and naloxone. Future work may identify appropriate interventions that can be introduced to extend time-to-first prescription opioid use among patients.

Indexed as

AdultBuprenorphine, Naloxone Drug CombinationDepressionFemaleFollow-Up StudiesHumansLatent Class AnalysisLongitudinal StudiesMaleMiddle AgedNarcotic AntagonistsOpioid-Related DisordersPainPredictive Value of TestsRecurrenceBuprenorphine, Naloxone Drug CombinationNarcotic AntagonistsBuprenorphine and naloxone treatmentDepressionGrowth mixture modelingOpioid substitution treatmentPainPrescription opioid use disorderSurvival

Identifiers

PMID32135429
PMCPMC7173998
OpenAlexW3010475984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.